Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

JFDI Nov. 14 at 4:38 PM

$NAMS Daily/weekly engulfer

0 · Reply

masonat Nov. 12 at 9:25 PM

$NAMS Sounds like we might get details for alzheimer's study in Q1 26

0 · Reply

masonat Nov. 10 at 2:58 PM

$NAMS Decided to trim my position a bit given the stock is already close to my original PT. Not a ton of room for a premium unless BP gives value to alzheimer's and no major catalysts for a year.

2 · Reply

masonat Nov. 8 at 3:57 PM

$AMGN $NAMS Reminder that decreasing LDL produces a very predictable reduction in MACE. Repatha performing exactly as expected based on its LDL lowering. Obicetrapib should get ~20% MACE in PREVAIL based on LDL alone. TBD if Obi's other differentiating features will produce additional MACE reduction.

0 · Reply

vu_jade Nov. 6 at 8:24 PM

$NAMS buy day

0 · Reply

JarvisFlow Nov. 6 at 4:24 PM

RBC Capital updates rating for NewAmsterdam Pharma Co ( $NAMS ) to Outperform, target set at 39 → 44.

0 · Reply

IN0V8 Nov. 6 at 5:33 AM

$NAMS Buy Piper Sandler raises PT to $60 from $37

0 · Reply

Petey3163 Nov. 5 at 7:48 PM

$ESPR what are we missing that will make this tank tomorrow? We all see the positive side but what can they do to pull the rug back to .70. $NAMS has a terrible report and it’s running.

0 · Reply

JarvisFlow Nov. 5 at 6:10 PM

Needham has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 40 → 46.

1 · Reply

d_risk Nov. 5 at 4:15 PM

$NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares - 10Q - Updated Risk Factors NAMS flags heightened risks from shifting U.S./EU healthcare regulations, drug pricing reforms like IRA and Medicare negotiations, and new U.S. tariffs on pharma imports, all threatening commercialization and profitability. #Pharmaceuticals #MarketRisk #TradeTariffs #DrugPricingReform #HealthcareRegulations 🟢 Added 🟠 Removed https://d-risk.ai/NAMS/10-Q/2025-11-05

0 · Reply

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

Nov 7, 2025, 4:01 PM EST - 9 days ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2025, 8:00 AM EST - 11 days ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Oct 30, 2025, 8:00 AM EDT - 18 days ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Sep 24, 2025, 8:00 AM EDT - 7 weeks ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 3, 2025, 10:22 PM EDT - 2 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 21, 2025, 2:41 AM EDT - 3 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 18, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 6, 2025, 7:00 AM EDT - 3 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Jul 30, 2025, 8:25 AM EDT - 3 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 9, 2025, 7:00 AM EDT - 5 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

May 27, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 14, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2025, 7:15 AM EDT - 6 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Apr 30, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Mar 31, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 9 months ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 9 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 9 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 9 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 1 year ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 6:55 AM EST - 1 year ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 1 year ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Feb 28, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 13, 2024, 10:40 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 1, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Nov 13, 2023, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

JFDI Nov. 14 at 4:38 PM

$NAMS Daily/weekly engulfer

0 · Reply

masonat Nov. 12 at 9:25 PM

$NAMS Sounds like we might get details for alzheimer's study in Q1 26

0 · Reply

masonat Nov. 10 at 2:58 PM

$NAMS Decided to trim my position a bit given the stock is already close to my original PT. Not a ton of room for a premium unless BP gives value to alzheimer's and no major catalysts for a year.

2 · Reply

masonat Nov. 8 at 3:57 PM

0 · Reply

vu_jade Nov. 6 at 8:24 PM

$NAMS buy day

0 · Reply

JarvisFlow Nov. 6 at 4:24 PM

RBC Capital updates rating for NewAmsterdam Pharma Co ( $NAMS ) to Outperform, target set at 39 → 44.

0 · Reply

IN0V8 Nov. 6 at 5:33 AM

$NAMS Buy Piper Sandler raises PT to $60 from $37

0 · Reply

Petey3163 Nov. 5 at 7:48 PM

$ESPR what are we missing that will make this tank tomorrow? We all see the positive side but what can they do to pull the rug back to .70. $NAMS has a terrible report and it’s running.

0 · Reply

JarvisFlow Nov. 5 at 6:10 PM

Needham has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 40 → 46.

1 · Reply

d_risk Nov. 5 at 4:15 PM

0 · Reply

masonat Oct. 31 at 6:34 PM

$NAMS You might have also noticed that the homozygote group is the only one to show a *decrease* in p-tau217 from baseline while all the other groups simply showed a smaller increase compared to placebo. This is likely because the homozygotes had higher baseline p-tau217 of ~0.50, which is a level that correlates with the presence of amyloid plaques. The fact that it decreased suggests that obi helps to clear plaques for people who already have some level of disease. The other groups don't have baseline disease on average, so you wouldn't expect to see a reduction from baseline.

0 · Reply

masonat Oct. 31 at 6:22 PM

$NAMS While we wait out this catalyst desert, let's take some time to appreciate the alzheimer's data. One thing I find impressive is that APOE4 carriers, who have ~3x higher risk of AD, had slower progression of p-tau217 than the general population on placebo.

0 · Reply

Doozio Oct. 31 at 12:58 PM

$NAMS HTFryday to bust out then yo $AXSM body NXT week while market 🧙s are shorting da SPY like 🐑 on the DLO? 🍿. Bless da 🐑 during 🐒🍌🧠⏰♾️

0 · Reply

OptionRunners Oct. 30 at 6:44 PM

$NAMS Buyer of the December 19th $25/$55 call spreads 5,000 times for $14.00 ahead of earnings on 11/5

0 · Reply

Digger75 Oct. 29 at 4:49 PM

$NAMS

0 · Reply

Digger75 Oct. 29 at 3:14 PM

$NAMS 52.00 come on

0 · Reply

Digger75 Oct. 28 at 2:23 PM

$NAMS

0 · Reply

Digger75 Oct. 28 at 12:40 PM

$NAMS

0 · Reply

Digger75 Oct. 27 at 7:11 PM

$NAMS

0 · Reply

Good2go Oct. 27 at 6:07 PM

$NAMS Nice to see a biotech with a chart that looks like a growth stock for a change. https://finviz.com/quote.ashx?t=NAMS&ty=c&ta=1&p=d

0 · Reply

Digger75 Oct. 27 at 1:07 PM

$NAMS

0 · Reply

notreload_ai Oct. 20 at 3:57 PM

$BOLT , $NAMS ... H.C. Wainwright initiates coverage on Bolt Biotherapeutics and NewAmsterdam Pharma with Buy ratings, highlighting innovative treatments in development. https://notreload.xyz/bolt-bio-newamsterdam-get-hc-wainwright-buy-ratings/

0 · Reply

Market Cap	4.35B
Revenue (ttm)	45.56M
Net Income (ttm)	-241.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-530.29%
Debt to Equity Ratio	0.00

Volume	1,576,800
Avg Vol	1,159,998
Day's Range	N/A - N/A
Shares Out	113.39M
Stochastic %K	59%
Beta	0.05
Analysts	Strong Sell
Price Target	$45.92